GlassScriptPhysician profile
Heather Barzo
NPI 1326506957
$4,868.85
in general payments reported to CMS, 2019-2025
28 companies · $797 in 2025
The $797 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,199 · 2022: $532 · 2023: $1,030 · 2024: $1,311 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.64 |
| Travel and Lodging | $247.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,529.12 | 2021-2025 | Intracept, Superion Indirect Decompression System, General - Therapies |
| Abbvie INC. | $614.40 | 2022-2025 | |
| Relievant Medsystems, INC. | $568.95 | 2021-2023 | Intracept |
| Collegium Pharmaceutical, INC. | $463.71 | 2021-2025 | Belbuca |
| Vertos Medical, INC. | $216.05 | 2022-2024 | Mild Device Kit |
| Tersera Therapeutics LLC | $167.82 | 2023-2025 | Prialt |
| Biohaven Pharmaceuticals, INC. | $149.18 | 2021 | |
| Medtronic, INC. | $144.70 | 2021-2022 | |
| Radius Health, INC. | $142.48 | 2021-2024 | Tymlos |
| Allergan, INC. | $98.47 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $98.42 | 2021 | |
| Merz North America, INC. | $84.51 | 2021 | |
| Amgen INC. | $84.04 | 2021-2022 | |
| Lundbeck LLC | $81.78 | 2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $73.48 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.08 | 2023-2024 | |
| Orexo US, INC. | $64.23 | 2024 | Zubsolv |
| Stryker Corporation | $30.86 | 2025 | Optablate |
| Fidia Pharma USA INC. | $25.12 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $23.27 | 2024 | |
| Almatica Pharma LLC | $19.43 | 2025 | Teriparatide |
| Ibsa Pharma INC. | $18.87 | 2024 | Licart, Tirosint |
| Biohaven Pharmaceutical Holding Company LTD. | $18.81 | 2022 | |
| Eisai INC. | $18.01 | 2021 | |
| Spinal Simplicity, LLC | $17.74 | 2025 | Ha Minuteman G3-R |
| Valinor Pharma, LLC | $16.91 | 2025 | Movantik |
| Pacira Pharmaceuticals Incorporated | $16.05 | 2024 | Iovera, Zilretta, Exparel |
| Redhill Biopharma INC. | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Barzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.